Abstract:
A process for production of plasmid pLCI comprises (a) isolating mRNA from human placentatissue, (b) preparing 2 chains of cDNA from the obtd. mRNA, (c) attaching (dC)n tail to the cDNA and subjecting it to recombination with plasmid vector, (d) transforimg E. coli with the recombinant plasmid, and (e) selecting clones having human lipocortin I coding gene in the transformant E. coli. Using the plasmid pLCI, human lipocortin I can be produced in soluble form. Lipocortin is useful as an anti-inflammatory protein.
Abstract:
A fragment having -300 base pairs was obtained from a plasmid, PILM 7, cut by XbaI and PvuII. On the other hand, a fragment having - 4,500 base pairs was obtained from aplasmid, pNK2, treated with XbaI and PvuII. Both of the fragments were ligated and inserted into a proper strain to get pNKM 21. pNKM 21 was inserted into M 5248 strain to get KCTC 8258 P strain followed by culturing it to give a interleukin-2 contg. serine at 125-position instead of cystein.